Holen Sie sich die Stockscreener-App
3.80
4.04%
-0.16
Schlusskurs vom Vortag:
$3.96
Offen:
$3.85
24-Stunden-Volumen:
935.41K
Relative Volume:
1.78
Marktkapitalisierung:
$1.18B
Einnahmen:
$548.10M
Nettoeinkommen (Verlust:
$69.50M
KGV:
16.50
EPS:
0.2303
Netto-Cashflow:
$-137.90M
1W Leistung:
-7.54%
1M Leistung:
-27.06%
6M Leistung:
-52.20%
1J Leistung:
-65.77%
1-Tages-Spanne:
$3.65
$3.88
1-Wochen-Bereich:
$3.65
$4.17
52-Wochen-Spanne:
$3.65
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.80 | 1.23B | 548.10M | 69.50M | -137.90M | 0.2303 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.26B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.93 | 54.44B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.61 | 48.41B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.28 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
498.65 | 22.12B | 3.13B | 1.27B | 1.12B | 26.39 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-11-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Eingeleitet | UBS | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech : Managers' transactionsALVOTECH - marketscreener.com
Alvotech’s Biosimilar Bet: Why Wall Street Is Suddenly Watching - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at 3.89 USD - Investing.com
Alvotech Discloses Intra-Group Transfer of 2.7 Million Shares Within Aztiq Group - TipRanks
Alvotech (NASDAQ: ALVO) discloses 2.7M-share intra-group transfer at $4.74 - Stock Titan
2.7 million Alvotech shares change hands inside owner group - Stock Titan
Alvotech (ALVO) Is Down 9.1% After FDA Rejects AVT05 Over Facility Issues and Legal Probe - simplywall.st
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech - GlobeNewswire
Alvotech begins European rollout of first-ever Simponi biosimilar Gobivaz - MSN
Alvotech (NASDAQ:ALVO) Cut to Strong Sell at Zacks Research - Defense World
Alvotech (NASDAQ:ALVO) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Alvotech stock hits 52-week low at $4.31 amid challenging year - Investing.com Australia
Alvotech (NASDAQ:ALVO) Reaches New 1-Year LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Trading Down 5.7%Here's Why - MarketBeat
Alvotech (ALVO): A 378% Upside Potential In The Biosimilar Market - DirectorsTalk Interviews
Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide? - simplywall.st
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump - Yahoo Finance
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook - Yahoo Finance
How Alvotech Equity Warrant stock performs during Fed tightening cyclesEarnings Overview Summary & Free Safe Capital Growth Stock Tips - mfd.ru
Can Alvotech Equity Warrant maintain its current growth rateQuarterly Trade Summary & Accurate Entry and Exit Point Alerts - mfd.ru
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 - Finviz
Can Alvotech be recession proofJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
12 Best Penny Stocks That Will Skyrocket - Insider Monkey
Is Alvotech the Next Big Biotech Rocket or Just Hype? Real Talk on This Viral Underdog Stock - AD HOC NEWS
How Alvotech (ALVO) Affects Rotational Strategy Timing - Stock Traders Daily
Alvotech’s AVT03 Biosimilar Gains European Approval - MSN
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Alvotech Announces Increase in Number of Own Shares - ChartMill
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech - GlobeNewswire
Press releases provided by CNW - Techaeris
Aug Drivers: What is the Moat Score of Alvotech Equity WarrantQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Alvotech Faces Securities Claims Investigation - Intellectia AI
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - morningstar.com
Alvotech Enters Supply and Commercialization Agreements for Canada and Australia & New Zealand Covering Multiple Biosimilar Candidates - 富途牛牛
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)? - simplywall.st
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio - MSN
Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings - Citeline News & Insights
Private Equity Firms Are Alvotech's (NASDAQ:ALVO) Biggest Owners and Were Hit After Market Cap Dropped US$63m - 富途牛牛
Alvotech Hits Pivotal Milestone With Positive PK Data for Entyvio Biosimilar AVT80 - TipRanks
Alvotech (NASDAQ: ALVO) posts positive pivotal data for Entyvio biosimilar - Stock Titan
Alvotech Reports Positive Top-line Pharmacokinetic Study Results For AVT80, A Biosimilar To Entyvio - Nasdaq
Why Is ALVO Stock Rising Pre-Market Today? - Stocktwits
Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Alvotech Reports Positive Results for AVT80 Clinical Study - Intellectia AI
Fuji Pharma Lifts Sales Outlook but Slashes Profit Forecast on Alvotech Valuation Loss - TipRanks
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® - The Manila Times
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):